

# Karyopharm to Host Conference Call to Discuss Selinexor (KPT-330) Data Presented at ESMO 2014

**- Phase 1 Clinical Data in Prostate Cancer and Other Solid Tumors -**

**- Conference Call and Interactive Webcast Scheduled for Monday, September 29, 2014 at 4:30pm ET -**

NEWTON, Mass., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, invites investors and the general public to participate in a conference call and interactive webcast on Monday, September 29, 2014 at 4:30pm ET to discuss Phase 1 clinical data for Selinexor (KPT-330) in advanced solid tumors, including chemotherapy refractory, castrate-resistant prostate cancer, which were presented at the 2014 Congress of the European Society for Medical Oncology (ESMO). Karyopharm's management team will be joined on the call by Christopher J. Logothetis, M.D., Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center and the principal investigator for the study.

To access the conference call, please dial (855) 437-4406 or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 11655910. The interactive webcast will be available on the Investors & Media section of the company's website, [investors.karyopharm.com/events.cfm](http://investors.karyopharm.com/events.cfm)

An archived webcast will be available on the Company's website approximately two hours after the event.

## About Selinexor

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound. Selinexor functions by inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. Over 450 patients have been treated with Selinexor in Phase 1 and Phase 2 clinical trials in advanced hematologic malignancies and solid tumors. Additional Phase 1 and Phase 2 studies are ongoing or currently planned and three registration-directed clinical trials in hematological indications have started enrolling patients or are expected to begin enrollment during 2014. The latest clinical trial information for Selinexor is available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. SINE™ compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information about Karyopharm, please visit [www.karyopharm.com](http://www.karyopharm.com).

CONTACT: Justin Renz

(617) 658-0574

[jrenz@karyopharm.com](mailto:jrenz@karyopharm.com)

Gina Nugent

(617) 460-3579

[nugentcomm@aol.com](mailto:nugentcomm@aol.com)

---

<https://investors.karyopharm.com/2014-09-25-Karyopharm-to-Host-Conference-Call-to-Discuss-Selinexor-KPT-330-Data-Presented-at-ESMO-2014>